Cytokinetics, Incorporated

Valuation Analysis

About the Company

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with he

Cytokinetics, Incorporated Stock at a Glance

Cytokinetics, Incorporated (CYTK) is currently trading at $70.15 with a market capitalization of $9.5B. The 52-week range spans from $31.99 to $80.20; the current price is 12.5% below the yearly high. Year-over-year revenue growth stands at +1125.8%.

💰 Dividend

Cytokinetics, Incorporated currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

20 analysts rate Cytokinetics, Incorporated (CYTK) on consensus: Buy. The average price target is $104.70, implying +49.25% from the current price. Analyst price targets range from $69.00 to $146.00.

Cytokinetics, Incorporated: The Investment Case in Detail

Cytokinetics, Incorporated (CYTK) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 1125.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Buy with an average price target implying roughly 49.25% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Short interest sits at 17.65% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

What to Watch Next

• The analyst consensus price target implies 49.25% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (17.65%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Cytokinetics, Incorporated?

Compare top-rated brokers — low fees, trusted providers, fully regulated.